Puretech initiates phase 2 trial of lyt-100 (deupirfenidone) in long covid respiratory complications and related sequelae

Boston--(business wire)--puretech (nasdaq: prtc) initiated a global, phase 2 trial of lyt-100 (deupirfenidone) in long covid respiratory complications and related sequelae.

PRTC Ratings Summary

PRTC Quant Ranking